South Korea – Draft of Regulation on Safety Standards for Cosmetics
South Korea has open for comments its draft of the Regulation on Safety Standards, etc. for Cosmetics. This draft proposes new prohibited ingredients, new restrictions on other ingredients and the management of unintentionally added ingredients.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate
Linkedin Instagram Facebook Address-card

SOUTH KOREA LEGAL FRAMEWORK ON COSMETIC PRODUCTS

In South Korea, the Cosmetics Act represents the main legal regulatory framework for cosmetics. There are other regulations, standards and guidance documents that support this Act and which allow the country to have a comprehensive framework to manage this type of products. The Cosmetics Act provides standards for the manufacture, importing and sale of cosmetics and cosmetic ingredients, including detailed requirements for the labelling and advertising of products. The Ministry of Food and Drug Safety (MFDS) is the competent authority that enacts and executes cosmetic regulations in South Korea, including the register of functional products. The South Korean Pharmaceutical Traders Association (KPTA) is responsible for issuing importing cosmetic approvals and supervising cosmetic trading. (see previous post)

The use of PVC materials and coloured PET bottles is banned in South Korea since the end of 2019. Since then companies are also required to evaluate the packaging material grade (Act on the Promotion of Saving and Recycling Resources). In July 2021, the Guideline on Recycling Symbols and Standards of Labelling Quality was issued by the Ministry of Environment (MOE) and will come into effect at the beginning of next year (January 1st, 2022). Previously, in March 2021, MOE issued the Structure of Packaging Material Guide, which was already implemented. (see previous post)

DRAFT REGULATION ON SAFETY STANDARDS, ETC. FOR COSMETICS

The draft of Regulation on Safety Standards, etc. for Cosmetics proposes the prohibition of some ingredients, new restrictions on other ingredients and the management of unintentionally added ingredients.

A notification to solicit public opinions on this draft Regulation was issued by the Ministry of Food and Drug Safety (MFDS) on December 2021. The deadline for comments was set at 17th January.

Among the new prohibited ingredients are eight perfluorinated compounds (e.g. perfluorononanoic acid, nickel(II) trifuoroacetate, ammonium perfluoronnonanoate, etc.), persistant pollutants (as stipulated in Article 2 of Persistent Organic Pollutants Control Act) and 1,2,4-Trihydroxybenzene. In the draft Regulation are specified restrictions on some colorants in hair dye products (with proposed use limits) and it is also specified that Benzalkonium Chloride shall not be used in spray-type cosmetics.

Critical Catalyst has a team of regulatory experts that can help you place your cosmetic products in the South Korean market. For any queries, not hesitate to contact us at info@criticalcatalyst.com.

References:

  1. South Korea Consults on Cosmetic Safety Standards. Chemlinked. Dec 30, 2021. Available at: https://cosmetic.chemlinked.com/news/cosmetic-news/south-korea-consults-on-cosmetic-safety-standards;
  2. Guideline on Recycling Symbols and Standards of Labeling Quality (Korean). 

further
reading
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
Guilherme Semedo February 24, 2023
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
Guilherme Semedo February 15, 2023
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
Guilherme Semedo February 13, 2023
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
Guilherme Semedo January 9, 2023
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
Guilherme Semedo December 13, 2022
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
Liliana Teles December 10, 2022
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
Filipa Ferreira October 11, 2022
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
Filipa Ferreira October 4, 2022

services

CONTACT US

  • info@criticalcatalyst.com
  • +351 91 200 43 51
    PT mobile network call
  • EUROPEAN UNION (HQ)
    679 Avenida da República
    4450-242 Matosinhos (PT)
  • UNITED KINGDOM
    49 Queen Victoria Street
    EC4N 4SA London (UK)